Your Article Summary
See Latest ArticlesHeight and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial
British Journal of Cancer, 07/02/09
Ahn J et al. - In a study to determine the association between height and risk of prostate cancer (PCa), results suggest that tallness is associated with increased risk for younger onset, aggressive PCa.
Methods- The association of height with PCa was prospectively examined among 34,268 men.
- Anthropometry was assessed at baseline and 2144 incident PCa cases were identified up to 8.9 yrs of follow-up.
- Tallness was not associated with risk of PCa or with risk of non-aggressive disease, but risk for aggressive PCa tended to be greater in taller men.
- This association was largely limited to men below the age of 65 yrs, although the number of cases was small and risk estimates were somewhat unstable.
Related Articles
The value of EZH2, p27kip1, BMI-1 and MIB-1 on biopsy specimens with low-risk prostate cancer in selecting men with significant prostate cancer at prostatectomy
BJU International, 11/17/09
Relevance Score: 91%
Red, processed meats linked to prostate cancer
MedLinePlus, 11/10/09
Relevance Score: 91%
A prospective study of lifetime physical activity and prostate cancer incidence and mortality
British Journal of Cancer, 11/02/09
Relevance Score: 91%
Association of 17 prostate cancer susceptibility loci with prostate cancer risk in Chinese men
The Prostate, 11/02/09
Relevance Score: 91%
Exercise and Prostate Cancer Risk in a Cohort of Veterans Undergoing Prostate Needle Biopsy
The Journal of Urology, 10/19/09
Relevance Score: 91%
Today in Renal/Urologic...keeping you current
Receive free subspecialty "5-minute updates" via email
Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension
Human Pathology, 12/19/09
Papillary renal cell carcinoma with diffuse clear cells and thyroid-like macrofollicular areas
Annals of Diagnostic Pathology, 12/19/09
Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence
Medical Oncology, 12/17/09